Rabbiosi G, Carcaterra A, Bellosta M
Int J Tissue React. 1986;8(2):141-3.
A series of 39 patients with CTCL was treated with PUVA over a period of 5 years, comprising 6 patients in stage IA, 13 in stage IB, 15 in stage IIA and 5 in stage IIB. PUVA treatments were administered four times weekly until clearing; a maintenance therapy employed 2 to 1 exposures per week for 2 months. Complete clinical and histological examinations were taken. We obtained a complete remission in all stage IA patients, and a partial remission in stage IB and IIA patients, who required longer treatment schedules and more frequent maintenance therapy. Stage IIB patients required additional local and/or systemic therapy to achieve a partial remission. Recurrences were observed in 33% stage IA patients, in 84% stage IB patients and in all stage IIA and IIB patients. They responded to new induction phases only in early-stage CTCL. PUVA is well accepted by patients, and compares well with other treatments.
39例蕈样肉芽肿患者在5年期间接受了补骨脂素加紫外线A（PUVA）治疗，其中IA期6例，IB期13例，IIA期15例，IIB期5例。PUVA治疗每周进行4次，直至皮疹消退；维持治疗每周进行2至1次，持续2个月。进行了完整的临床和组织学检查。所有IA期患者均获得完全缓解，IB期和IIA期患者部分缓解，这些患者需要更长的治疗疗程和更频繁的维持治疗。IIB期患者需要额外的局部和/或全身治疗以实现部分缓解。IA期患者复发率为33%，IB期患者为84%，IIA期和IIB期患者全部复发。他们仅在蕈样肉芽肿早期对新的诱导治疗阶段有反应。PUVA疗法患者接受度良好，与其他治疗方法相比效果较好。
